Dr Haddad on the Efficacy of Asciminib in Newly Diagnosed CML

“The primary end point of the study…was the rate of 12-month major molecular response, which was achieved by 69% of the patients. [Additionally, 39%] of the patients achieved what we call deep molecular remission.”

Fadi Haddad, MD, an assistant professor and co-leader of the Section of Chronic Myeloid Leukemia in the Department of Leukemia in the Division of Cancer Medicine at The University of Texas MD Anderson Cancer Center, discussed findings from an ongoing phase 2 trial (NCT06236724) investigating asciminib (Scemblix) in patients with newly diagnosed chronic myeloid leukemia.